Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies.
about
The role of oxidative stress in Parkinson's diseaseNeuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson diseaseDPDR-CPI, a server that predicts Drug Positioning and Drug Repositioning via Chemical-Protein InteractomeMonoamine oxidases as sources of oxidants in the heartPopulation pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease.Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.Natural products from marine organisms with neuroprotective activity in the experimental models of Alzheimer's disease, Parkinson's disease and ischemic brain stroke: their molecular targets and action mechanisms.Activity-based probes for studying the activity of flavin-dependent oxidases and for the protein target profiling of monoamine oxidase inhibitorsEvaluation of the antioxidant capacity of synthesized coumarins.Antidepressants are neuroprotective against nutrient deprivation stress in rat hippocampal neurons.Synthesis, Biochemistry, and Computational Studies of Brominated Thienyl Chalcones: A New Class of Reversible MAO-B Inhibitors.Comparative Activity-Based Flavin-Dependent Oxidase Profiling.Body fat reduction without cardiovascular alteration in mice under oral treatment by the MAO inhibitor phenelzine.Glitazones inhibit human monoamine oxidase but their anti-inflammatory actions are not mediated by VAP-1/semicarbazide-sensitive amine oxidase inhibition.Imine Deaminase Activity and Conformational Stability of UK114, the Mammalian Member of the Rid Protein Family Active in Amino Acid Metabolism.
P2860
Q24307946-B7BBE9A6-7C82-401D-9B9D-86F1AEEFD6FCQ28259054-84673E56-1BC9-4D5D-A6B5-6A2266717175Q28822352-51D37080-F4DD-4AC5-BFC2-B70B229709FBQ33723676-D48C52C0-8CA2-4765-895F-D3DE973D1444Q37303004-040D0FF5-3F72-4C90-8280-983C8E3C7AADQ38067297-74214A69-4873-47C5-A0A5-AEE8F9D1ADE0Q38263124-0D40BE77-45AB-49EC-8BC4-F188C862A027Q41908572-C63FE0D1-1E31-45E1-A730-AECBA2FDCB0DQ42237924-81147892-4DD5-4E67-9C59-29F44618A04FQ46511170-CD35B4B3-FD92-42C7-A8D3-430B9B3B2A41Q48755719-90E2F811-4CAF-442F-A5EB-0716A24EC663Q48957959-41C55622-4240-4597-BF78-64BB067366F8Q51244360-FAC40F66-9760-4EA3-96A4-7FB5A15EF7AFQ53649555-30450B77-D409-4396-9273-F1DF880A6C74Q54962323-0FBB3BA9-F7DC-4B28-A077-04C84F071172
P2860
Lights and shadows on monoamine oxidase inhibition in neuroprotective pharmacological therapies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Lights and shadows on monoamin ...... ive pharmacological therapies.
@en
Lights and shadows on monoamin ...... ive pharmacological therapies.
@nl
type
label
Lights and shadows on monoamin ...... ive pharmacological therapies.
@en
Lights and shadows on monoamin ...... ive pharmacological therapies.
@nl
prefLabel
Lights and shadows on monoamin ...... ive pharmacological therapies.
@en
Lights and shadows on monoamin ...... ive pharmacological therapies.
@nl
P2093
P1476
Lights and shadows on monoamin ...... ive pharmacological therapies.
@en
P2093
Dale E Edmondson
Daniele Bonivento
Erika M Milczek
P304
P356
10.2174/156802611798184355
P577
2011-11-01T00:00:00Z